Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C

Advanced or metastatic disease is common in both oesophagogastric and colorectal cancers, with poor 5-year survival despite palliative chemotherapy. We have investigated the sensitivity of gastrointestinal tumours to gemcitabine in combination with mitomycin C (GeM), using a modified ex vivo ATP-bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitehouse, P A, Mercer, S J, Knight, L A, Di Nicolantonio, F, O'Callaghan, A, Cree, I A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395279/
https://www.ncbi.nlm.nih.gov/pubmed/14676810
http://dx.doi.org/10.1038/sj.bjc.6601403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395279/
https://www.ncbi.nlm.nih.gov/pubmed/14676810
http://dx.doi.org/10.1038/sj.bjc.6601403

Ejemplares similares